Roivant (ROIV) Q4 FY26 earnings call

Roivant delivered a quarter of significant clinical and financial milestones, highlighted by unexpectedly strong open-label data for IMVT-1402 in refractory rheumatoid arthritis and the substantial Moderna settlement. The company is advancing its pipeline with brepocitinib's imminent launch and mosliciguat's Phase II data readout, while navigating the complexities of trial design and regulatory discussions for its diverse portfolio.